With one of Europe's largest pharmaceuticals teams, we provide expertise to pharmaceutical companies from global corporations to start-ups in accelerating their growth and maintaining their competitive edge. Our knowledge and expertise in the pharmaceutical industry are extensive. Clients value our pragmatic and strategic advice based on a thorough understanding of the technical, scientific, IP, and the regulatory landscape in which they operate.
Securing a sustainable future for our pharmaceutical clients is a priority, and we achieve this in several ways. We regularly challenge regulators' decisions and undertake judicial reviews, combined with our innovative collaborations with highly regarded specialists in dispute resolution. Many of our lawyers have science degrees and Ph.Ds or have worked in-house at leading global pharmaceutical companies giving them a competitive advantage and reliable hands-on knowledge and insights.
We keep our clients on the right side of regulatory compliance, enable strategic alliances and clinical trials, advise on supply and distribution, and all intellectual property rights aspects. We also provide expertise in restructuring, manufacture, product portfolio divestments, acquisitions, IPOs, and M&A.
Global pharmaceutical companies rely on our patent litigators' expertise to resolve both offensive and defensive multi-jurisdictional patent litigation. Similarly, we work alongside pharmaceutical companies to resolve commercial disputes through the courts or international arbitration.
Our work's breadth is extensive and covers additional specialist areas that are invaluable to our client's growth and the protection and commercialization of valuable assets. Our IP licensing and life sciences commercial specialists advise on structuring, drafting, and negotiating on the commercialisation of products for pharmaceutical clients. Our specialist life sciences corporate team secures innovative pharmaceutical companies' futures through strategic funding solutions, including working with reputed angel investors and venture capitalists, investments from, and buyouts by private equity houses and through strategic asset disposals and acquisitions and M&A transactions.